Teva Pharmaceutical Industries (TEVA) EBITDA (2016 - 2026)

Teva Pharmaceutical Industries has disclosed EBITDA across 11 years of filings, most recently posting $652.0 million for Q1 2026.

• Quarterly EBITDA rose 25.63% year-over-year to $652.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 427.42% YoY) and the FY2025 annual result came in at $2.2 billion, up 811.88% from the prior year.
• EBITDA improved to $652.0 million in Q1 2026, from $300.0 million in the prior quarter.
• Over five years, EBITDA peaked at $882.0 million in Q3 2025 and troughed at -$967.0 million in Q2 2022.
• A 5-year average of $43.6 million and a median of -$5.0 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA plunged 1576.92% — and 2025, when it surged 9200.0%.
• Tracing TEVA's EBITDA over 5 years: stood at -$940.0 million in 2022, then soared by 180.43% to $756.0 million in 2023, then plunged by 103.84% to -$29.0 million in 2024, then soared by 1134.48% to $300.0 million in 2025, then jumped by 117.33% to $652.0 million in 2026.
• Business Quant data shows TEVA's EBITDA at $652.0 million in Q1 2026, $300.0 million in Q4 2025, and $882.0 million in Q3 2025.